Breaking Finance News

Horizon Pharma PLC (NASDAQ:HZNP) has been downgraded to Market Perform in a statement by Cowen and Company earlier today.

Cowen and Company has downgraded Horizon Pharma PLC(NASDAQ:HZNP) to Market Perform in a statement released on 9/16/2016.

Previously on Tuesday September 13 2016, Mizuho Securities reported about Horizon Pharma PLC(NASDAQ:HZNP) bumped the target price from $30.00 to $33.00 that indicated a possible upside of 0.75%.

Only yesterday Horizon Pharma PLC (NASDAQ:HZNP) traded 0.79% lower at $19.58. The company’s 50-day moving average is $20.23 and its two hundred day average is $17.53. With the last stock price close up 10.81% from the 200-day moving average, compared with the S&P 500 which has decreased -0.01% over the date range. 1,298,780 shares of Horizon Pharma PLC exchanged hands, down from ann average trading volume of 4,266,340.

See Graph Below:

Horizon Pharma PLC (NASDAQ:HZNP)

With a market cap of $0.0, Horizon Pharma PLC has a 52 week low of $12.86 and a one-year high of $32.34 with a P/E ratio of 0.

In addition to Cowen and Company reporting it’s stock price target, a total of 13 analysts have reported on Horizon Pharma PLC. The 12-month target price is $30.23 with four firms rating the company a strong buy, six firms rating the stock a buy, one analyst rating the stock a hold, one brokerage rating the company to underperform, and lastly 0 analystsrating the company as sell.

General Company Details For Horizon Pharma PLC (NASDAQ:HZNP)

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units. Its segment focuses on the identification, development, acquisition and commercialization of differentiated and accessible medicines. Its marketed medicines include ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), MIGERGOT (ergotamine tartrate and caffeine suppositories), PENNSAID (diclofenac sodium topical solution) 2% w/w, or PENNSAID 2%, RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). It also developed DUEXIS and RAYOS, and known as LODOTRA.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *